CTOs on the Move

HMA Inc

www.hma-inc.com

 
HMA Inc is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.hma-inc.com
  • 1600 W Broadway Rd Ste 300
    Tempe, AZ USA 85282
  • Phone: 480.921.8944

Executives

Name Title Contact Details

Similar Companies

Somnia Inc

Somnia Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New Rochelle, NY. To find more information about Somnia Inc, please visit www.somniainc.com

Labyrinth Health Care Group

Labyrinth Health Care Group is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inland Imaging Svc

Inland Imaging Svc is a Grand Terrace, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Retreat Nursing Home

Retreat Nursing Home is a Monticello, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.